This is a unique opportunity to study for a clinical PhD or carry out a period of postdoctoral research focused on translating scientific discoveries into new treatments for rare mitochondrial disorders as part of a new national rare disease centre funded by LifeArc.
The Cambridge Clinical Mitochondrial Research Group (MitoCAMB) studies the genetic basis and mechanisms of mitochondrial diseases and other rare inherited neurological disorders. Our research group is embedded within the Department of Clinical Neurosciences and the MRC Mitochondrial Biology Unit, University of Cambridge. Our research programme aims to better understand the mechanisms of mitochondrial diseases and other neurodegenerative/neuromuscular diseases, and to develop new and effective treatments for affected patients through investigator-led experimental medicine studies, novel gene therapy approaches, and clinical trials.
The group was recently awarded a £7.5 million LifeArc Translational Rare Disease Centres Award for the next 5 years with our partners at UCL, the University of Newcastle, the Lily Foundation and MDUK. Together, we aim to establish a national platform to translate novel treatment strategies and biomarkers into clinical trials. This platform will improve mitochondrial disease diagnosis nation-wide, connecting patient groups, knowledge and infrastructure to accelerate the clinical translation of new treatments.
More info & applicationPosted on 09/09/2024
